Study: Cannabis Treats MSS

Technician with medical cannabis
A study published in this month’s issue of the journal European Neurology and published online by the U.S. National Institute of Health found that muscle stiffness multiple sclerosis marijuanaSativex – a medicinal spray made from the cannabis plant – can be an effective treatment option for “moderate to severe multiple sclerosis spasticity (MSS)”.

According to researchers: “Nabiximols (Sativex®), a cannabinoid-based oromucosal spray, is an add-on therapy for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other medications. The primary objective was to provide real-life observational data of clinical experience of nabiximols in contrast to formal clinical trials of effectiveness.”

Researchers used an non-intervention research method with “a follow-up period of 3-4 months”; in total, 335 patients were assessed.

After conducting the study, it was concluded that; “Real-life data confirm nabiximols as an effective and well-tolerated treatment option for resistant MSS in clinical practice.”

The study was conducted by researchers at the Neurological Rehabilitation Center Quellenhof in Germany.

Another study published earlier this year by the journal Expert Review of Neurotherapeutics came to a similar conclusion, finding nabiximois to be an effective treatment for multiple sclerosis spasticity.

About Douglas Slain

Doug received a JD from Stanford Law School, a MA from the University of Chicago, and a BA from DePauw University (Phi Beta Kappa). After practicing real estate and finance law at then Pillsbury, Madison & Sutro, he founded four national monthly law reporting titles now owned by Thomson-Reuters. He served two consecutive terms as chairman of the American Bar Association’s General Practice section’s Professional Responsibility Committee. Slain was an ABA-appointed rule of law consultant to the Ministry of Economy for the Republic of Latvia as its secured transactions adviser. He taught briefly at Stanford Law School as an adjunct clinical law professor. Slain has been the managing partner of Private Placement Advisors since August 2009. In January 2013 he founded Outliers Network.

Leave a Reply

Your email address will not be published. Required fields are marked *